Business
BiomX CEO Issues Letter to Stockholders
BiomX Inc. (NYSE American: PHGE), today released the following letter from its Chief Executive Officer to stockholders.
About this update from Biomx Inc.
[{"type":"text","content":"CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunities","length":170,"tagName":"p"},{"type":"text","content":"DOVER, Del., March 19, 2026 /PRNewswire/ -- BiomX Inc. (NYSE American: PHGE), today released the following letter from its Chief Executive Officer to stockholders.","length":163,"tagName":"p"},{"type":"text","content":"Dear Stockholders,","length":18,"tagName":"p"},{"type":"text","content":"Over the past several weeks, BiomX has taken decisive steps to reshape its leadership, priorities, and financial structure. Leadership has evolved, strategic priorities have been sharpened, and we are taking concrete steps intended to improve the Company's financial and operational structure. These changes have not been easy, but they are necessary to put BiomX on a stronger and more disciplined path forward.","length":416,"tagName":"p"},{"type":"text","content":"Our goal is clear: to stabilize the Company's financial footing, simplify our capital structure, and position BiomX to pursue strategic opportunities with greater focus and discipline.","length":188,"tagName":"p"},{"type":"text","content":"One such change relates to the warrants issued in connection with the recent investment completed in December 2025. These warrants were originally structured with a five-year term. Following consideration, the Board, in agreement with the warrant holders, determined to amend the warrant structure so that the warrants will have a one-year exercise period with an adjusted exercise price of $1.00 per share.","length":407,"tagName":"p"},{"type":"text","content":"The details of this amendment are described in the Form 8-K filed on March 19, 2026. In practical terms, this change significantly shortens the timeline associated with these warrants. Long-dated warrants can create an overhang that may complicate how public investors evaluate the Company. By shortening the period to one year, BiomX is working towards the resolution of this overhang. The shorter duration also reduces the theoretical value of these warrants, as commonly measured by option pricing models.","length":508,"tagName":"p"},{"type":"text","content":"We believe this step aligns the interests of the Company and our investors while supporting a more efficient ...